

CURRICULUM VITAE

Sujith Kalmadi, M.D
 Ironwood Cancer & Research Centers, P.C.
 695 S. Dobson Road
 Chandler, Arizona 85224
 (480) 821-2838
 July 1, 2008 - Present

I. Clinical experience

<u>Year</u>	<u>Position</u>	<u>Institution</u>
1/19-present	Chief Medical Officer (Group of 74 multispecialty oncology providers in Arizona with about 650 employees)	Ironwood cancer and research centers,
6/08 –Present	Staff Physician	Medical Oncologist & Hematologist, Ironwood Cancer & Research Centers Chandler, Arizona
3/11-Present	Clinical Assistant Professor	Midwestern University, Arizona college of osteopathic medicine, Glendale, Arizona.
11/07 – 6/08	Clinical Assistant Professor	Baylor Medical College, Methodist Hospital / St. Luke’s Hospital, Texas Oncology/ US Oncology, Houston, Texas.
06/06-10/07	Associate Staff Physician	Solid tumor, hematologic oncology and blood disorders, Taussig Cancer Center, Cleveland Clinic Cleveland, Ohio
06/03-06/06	Fellow	Taussig Cancer Center, Cleveland Clinic, Cleveland Ohio
01/02-06/03	Chairman	Department of Medicine, Putnam Hospital, Palatka, Florida.
07/99-06/03	Staff physician	Putnam Hospital, Palatka, Florida.

II. Post-Graduate Education

<u>Year</u>	<u>Position</u>	<u>Institution</u>
2003-06	Fellow in Hematology-Oncology	Cleveland Clinic, Cleveland, Ohio
1995-99	Resident in Medicine-Pediatrics	Cleveland Clinic Foundation, Cleveland, Ohio
1994-95	Intern	Henry Ford Hospital, Detroit, Michigan

III. Education

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1993	M.B.B.S.	Kasturba Medical College, Mangalore, India.
1987	P.U.C	Mahatma Gandhi Memorial College, Udupi, India.

IV. Certification and Licensure

A. Certification

<u>Board</u>	<u>Date of certification</u>	<u>Number</u>
Medical Oncology	11/06 to 2016	188865
Hematology	11/07 to 2017	188865
Internal Medicine	11/99 to 2019	188865
USMLE	March 94	04975520

B. Licensure:

<u>State</u>	<u>Date</u>	<u>Perm./Temp.</u>	<u>Number</u>	<u>Expiration Date</u>
Arizona	4/4/2008	Permanent	38208	
Texas	11/30/07	Permanent	M8068	Expired
Ohio	4/29/99	Permanent	35-07-2739	Expired
Florida	5/8/99	Permanent	ME 77981	Expired

V. Professional Affiliations (including offices held)

<u>Year</u>	<u>Organization</u>
-------------	---------------------

2007-08	Member, Thoracic Oncology Research Committee, Southwest Oncology Group (SWOG)
2007-08	Member, Gastrointestinal Oncology Research Committee, Southwest Oncology Group
2005-08	Member, Information Technology Committee, American Society of Clinical Oncology.
2003-	Member, American Society of Hematology
2003-	Member, American Society of Clinical Oncology
2002-03	Chairman, Department of Medicine, Putnam Medical center, Palatka, Florida
2002-03	Chairman, Medical quality assurance committee, Putnam Medical center, Palatka, Florida
2001-03	Chairman, Total quality improvement committee, Family Medical center, Palatka, Florida
1999-	Member, American College of Physicians
1988	Treasurer, Anatomy Club, Kasturba Medical College
1985	President, Students council, Christian High School, Udupi, India

VI. Clinical Research Experience

- Principal investigator at several phase 2 and phase 3 clinical trials (listed below) at Ironwood Cancer and Research Centers, Arizona from 2009 to now.
- During work at Baylor involved in thoracic and gastrointestinal malignancies research at the USOncology research network and Baylor Medical College.
- During my work at the Cleveland Clinic (Taussig cancer center), I was the principal investigator of 9 clinical trials (3 investigator initiated, 6 Industry sponsored) in thoracic and gastrointestinal malignancies.

VII. Research Protocols: Sub-Investigator Responsibilities

1. Amgen Protocol 20060362: An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer (2008 -)
2. Pfizer Protocol A6181104: A Randomized, Phase 2B Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX as First-Line Treatment In Patients with Metastatic Colorectal Cancer (2008 -)
3. Abbott Protocol M10-301: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment (2009-)

4. Genentech Protocol TDM4370g/Roche Protocol BO21977: A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy (**EMILIA**) (2009-)
5. Novartis Protocol CRAD001Y2301: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole (**BOLERO 2**). (2009-)
6. Novartis Protocol CRAD001J2301: A Randomize Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer (**BOLERO 1**). (2009-)
7. Imclone Protocol CP12-0606/TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of iMC-1121 B Plus Docetaxel versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer. Protocol IMCL CP12-0606/TRIO-012. (2010 –)
8. Novartis Protocol CRADN2301 : A Randomized Double-Blind, Placebo-Controlled, Multicenter phase III Study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy (**PILLAR 2**) (2010 –)
9. GlaxoSmith Kline Protocol LPT112515: A Randomized, Phase III, Open-Label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer (**HALT-MBC**) (2010 –)
10. Peregrine Protocol PPHM 1001: A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 –)
11. Peregrine Protocol PPHM 0902: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 -)

VIII. Teaching Activities

A. Current teaching activities:

- Clinical Instructor – Midwestern Medical School, Glendale, Arizona

B. Former teaching activities:

- Cleveland clinic Foundation: Staff in thoracic and gastrointestinal malignancies. Conducted didactic teaching conferences and rounds with medical students, residents and fellows in hematology and medical oncology.
- Clinical teaching at St. Lukes Hospital with Baylor Medical College Fellows (Hematology and medical oncology), Residents (Internal Medicine) and medical students.
- Educational conference presentations (St. Lukes Hospital and Methodist Hospital)
- Clinical teaching at Methodist Hospital with Internal Medicine residents.

IX. Other Professional Activities (Boards, Editorships, Etc.)

<u>Year</u>	<u>Activity</u>
2007	Reviewer, American Board of Internal Medicine, Medical oncology subspecialty examination
2005	Reviewer, <i>Cancer</i>
2005	Reviewer, Journal of clinical oncology.

X. Honors and Awards

<u>Year</u>	<u>Honor</u>
2007	Outstanding teacher of the year award, Hematology-Oncology fellowship program, Taussig cancer center, Cleveland Clinic
2003	Received the Amgen fellow of the year fellowship grant award
1994	Passed all three USMLE (United stated medical licensing exam) in the top 10 th percentile
1993	Passed all the examinations of Medical school in first class
1985	Awarded a long-term scholarship (8 years) by the National Council of Educational Research and Training of India (NCERT) after having passed the National Talent Search Examination.

XI. Bibliography

A. Journal publications:

- (1) Afatinib versus Erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-8): an open -label randomized controlled phase 3 trial. *Lancet oncology*, 2015 Aug; 16 (8): 897-907. Turner et al. Paloma Study group. Collaborator.
- (2) Palbociclib in hormone receptor positive advanced breast cancer. *New England Journal of Medicine*. 2015 Jul 16; 373 (3): 209-19. Soria Et al. Lux Lung 8 investigators. Collaborator.
- (3) Predictors of clinical outcomes of resected ampullary adenocarcinoma : a single institution experience. Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. *Eur J Surg Oncol* 2011 Sep; 37 (9)
- (4) Clinical Utility of temozolimide in the treatment of malignant paraganglioma: a preliminary report. Bravo EL, Kalmadi SR, Gill I. *Horm Metab Res*. 2009 Sep;41(9):703-6. Epub 2009 Jun 17.
- (5) Evolving perspectives of the role of novel agents in androgen independent prostate cancer.

Kalmadi S, Raghavan D. Indian J Urol 2008 Jul; 24 (3): 303-8

- (6) Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the southwest oncology group (swog 9810). Kalmadi, S, Rankin, C, Kraut, M, Jacobs, A, Petrylak, D, Adelstein, D, Keohan, M, Taub, R and Borden, E. Lung Cancer 2008 May; 60 (2): 259-263.
- (7) Neoadjuvant Therapy for Hepatocellular Carcinoma: Is There an Optimal Approach? Almhanna, K, Kalmadi, S, Pelley, R, and Kim, R. Oncology; 2007 August; Volume 21, Number 9. Review.
- (8) Lenalidomide: the emerging role of a novel targeted agent in malignancies. Kalmadi, S., Baz, R., and Mahindra, A. Drugs Today (Barc). 2007 Feb;43(2):85-95. Review.
- (9) Epsilon Aminocaproic Acid reduces transfusion requirement in patients with thrombocytopenic hemorrhage. Kalmadi, S., Tiu, R., Lowe, C., and Kalaycio, M. Cancer: 2006; Volume 107; Issue 1; 136-40. Original article.
- (10) Phase I trial of three-weekly docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. Kalmadi, S., Davis, M., Dowlati, A., O'Keefe, S., Cline-Burkhardt, M., Pelley, R.J., Borden, E., Dreicer, R., Bukowski, R., and Mekhail, T. Investigational New drugs: 2006. Original article.
- (11) Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Kalmadi, S, Mc'Neill, G, Davis, M, Peereboom, D, Adelstein, D, Mekhail, T. Medical Oncology: 2006; Volume 23, No.3. Original article.
- (12) The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Kalmadi, S., and Hussein, M. Acta Haematologica; 2006; Vol. 116, 1-7. Review.
- (13) New biology of lung cancer: Prognostic factors and therapeutic impact: Kalmadi, S. Molecular Oncology Report, 2006.Review.
- (14) Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplants ever be discontinued. Gordon, S., LaRosa, S., Kalmadi, S., Arroliga, A., Avery, R., Truesdell-Larosa, L., and Longworth, D.L. Clinical Infectious diseases, 1999; 28 (2); 240-6. Original article.

B. Books and/or Chapters:

- (1) Uncommon tumors of the kidney in "Textbook of uncommon cancers- 3rd edition". Kalmadi, S., Zhou, M., Novick, A., and Bukowski, R. John Wiley and sons, 2005
- (2) Fundamentals of cancer treatment: Effects of chemotherapy on neoplastic cells in " Cancer in the spine: comprehensive care for spinal column tumors." Kalmadi, S., and Raghavan, D.Humana Press, 2005.

C. Abstracts:

- 1) Analysis of 140 cases with biliary tract cancer (BTC). K. Almhanna, R. Kim, S. Kalmadi, p. Elson, J. Dumot, M. Walsh, M. Henderson, R. J. Pelley. 2008 ASCO GI symposium.
- 2) Factors associated with tumor recurrence and 5-year postoperative survival in ampullary carcinoma: Cleveland Clinic Experience. A. Lazaryan, K. Almhanna, P. Elson, S. Kalmadi, D. Vogt, M. Walsh, M. Henderson, R. Pelley, R. Kim. 2008 ASCO GI symposium.
- 3) Is adjuvant radiation plus chemotherapy for resectable pancreatic adenocarcinoma associated with improved survival? The Cleveland Clinic experience. R. E. Tsao, K. Almhanna, A. Lazaryan, P. Elson, S. Kalmadi, R. J. Pelley, R. Kim, M. Walsh, M. J. Henderson, D. Vogt
- 4) Response to transarterial chemoembolization prior to liver transplantation or hepatic resection in patients with hepatocellular carcinoma. Almhanna, K, Golshayan, A, Sands, M, Levitin, A, Kim, R, Pelley, R, and Kalmadi,S. 2007 Annual ASCO meeting. Number 15114.
- 5) Nigro regimen treatment of squamous cell cancer of the anus.Kalmadi, S. Pelley, R, Kay, E, Saxton, J., Bukowski, R, Kim, R, Lavery, C and Fazio, V. 2007 Annual ASCO meeting. Number 14545.
- 6) Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. Kalmadi, S., Davis, M., Dowlati, A., O'Keefe, S., Cline-Burkhardt, M., Pelley, R.J., Borden, E., Dreicer, R., Bukowski, R., and Mekhail, T. 2006 annual ASCO meeting. Number 13027
- 7) Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer. McNeill, G., Kalmadi, S., Davis, M., Peereboom, D., Bukowski, R., and Mekhail, T. 2006 annual ASCO meeting. Number 17076.
- 8) Pilot study of SELDI-TOF in bone marrow failure syndromes. Kalmadi, S., Wu, R., Plasinova, M., Sloan, E., Galili, N., Raza, A., Maciejewski, J. 2005 ASCO annual meeting. Number 6547.
- 9) EACA is effective in controlling thrombocytopenic hemorrhage in patients with hematologic malignancies. Tiu, R., Kalmadi, S., Lowe, C., Sobecks, R., Bolwell, B., Lichtin, A., Kalaycio, M., Maciejewski, J., Advani, A., Sekeres, M., Pohlman, B. 2005 ASCO annual meeting. Number 6648
- 10) A pilot application of SELDI-TOF mass spectrometry in Bone marrow failure syndromes. Kalmadi, S., Wu, R., Nearman, Z., Elson, P., Sekeres, M., and Maciejewski, J. A American society of Hematology 2005 annual meeting. Number 3421.
- 11) Weekly docetaxel-gemcitabine as first line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study. Kalmadi, S., Mekhail, T., Adelstein, D., Giannini, C., Peereboom, D., Olencki, T., Davis, R, and Bukowski, R. 2004 ASCO annual meeting. Number

7236.

- 12) EACA reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Kalmadi, S., Tiu, R., Lowe, C., Sobecks, R., Bolwell, B., Lichtin, A., Hussein, M., Maciejewski, J., Advani, A., Sekeres, M., Andresen, S., Pohlman, B., Elson, P., and Kalaycio, M. American society of hematology 2004 annual meeting. Number 3938.

D. Special Presentations :

- (1) "Methods in clinical cancer research." Workshop by American society of clinical oncology (ASCO) and American Association for Cancer Research. Vail, Colorado 2007.
- (2) "Utility of SELDI proteomics in hematologic disorders" at the advances in proteomics in cancer research. American Association of cancer Research (AACR). Poster presentation. Key Biscayne, Florida. October 2004.
- (3) "The changing epidemiology and outcome of neutropenic fever." Poster presentation. Resident research day, Cleveland Clinic Foundation, May 1999.
- (4) "Cystic diseases of the kidney, from childhood to adult life." Poster presentation. Department of Nephrology grand rounds, April 1998, Cleveland Clinic.